Marián Mokáň, Peter Galajda
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, gliflozins, including canagliflozin, dapagliflozin and empagliflozin,
are a new class of diabetic medications indicated for the treatment of type 2 diabetes mellitus. Apart from
glycaemic control and low risk of hypoglycaemia, gliflozins have been shown to provide significant cardiovascular
benefit in patients with type 2 diabetes mellitus, which is explained by their influence on decreased risk of heart failure.
There is actual discussion about increased risk of distal amputation of lower extremities in patients treated by
gliflozins according to signal from study CANVAS with canagliflozine. The newest real word experience study the
OBSERVE-4D confirms benefits of all three gliflozines on heart failure and does not confirm increased risk of distal
amputations of lower extremities by canagliflozin treatment.